Business Weekly - Cambridge, UK

Shares in Cambridge pharma, CeNeS have gained another five per cent after the firm announced the recent release of two independent reports highlighting the benefits of its morphine replacement candidate, M6G.

The reports underlined the dangers of administering morphine to patients with reduced liver function or in combination with other common medications, areas in which CeNeS said it expects M6G to surpass the traditional pain treatment.

Neil Clark, CEO at CeNeS said: “These new papers show that morphine should be used carefully in patients with compromised liver function and in those taking a range of other drugs.”

M6G was recently granted an IND in the US, and has generated some positive results during the drug's Phase III trials in the UK.

“Our ongoing discussions with independent clinicians regarding M6G continue to confirm that it has the potential to be a very attractive new product for the treatment of post-operative pain,” said Clark.

The company's shares have risen over five per cent in value, growing 0.25p to 4.625.